Inavya is a groundbreaking brand that introduces AVATR®, a platform designed to revolutionize how users manage and leverage their personal data. With the assistance of a highly intelligent, digital version of themselves, individuals can take ownership of their data like never before. AVATR offers a range of benefits, including substantial cost savings, improved clinical outcomes, and increased patient engagement and retention.

One of the key features of AVATR is its AI technology, which unlocks the potential of digital twins to deliver personalized healthcare on a large scale. Doctors can easily input care and medication plans, simplifying the process for patients. AVATR empowers doctors to assess the effectiveness of medication based on each individual's lifestyle, biomarkers, and mental health, allowing for proactive intervention and care.

Patients can also rest assured that they are being cared for beyond their doctor visits. Inavya's target customers include public and private hospitals, specialist clinics, pharma, diagnostics, and insurance providers. What sets AVATR apart is its collaboration with clinical teams at world-leading hospitals, its medical device certification, and its use of Classical AI, Semantic Technology, and Quality Design.

Both patients and clinicians have full control over their AVATR experience. Inavya has already made significant strides, collaborating with top-rated hospitals globally and engaging with the NHS. Their hypertension proof of concept (POC) results have been published, solidifying their commitment to evidence-based medicine.

With £1 million in angel investment and grant funding, Inavya is poised to make a lasting impact in the healthcare industry. Please note that AVATR is a registered trademark of Inavya Ventures Ltd, and all rights are reserved